EATG » Hepatitis

Hepatitis

No consistent pattern of HBV reactivation with direct-acting antivirals for HCV

The largest case review to date of hepatitis B virus (HBV) reactivation associated with direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection found no consistent pattern in…

8-week sofosbuvir-velpatasvir-voxilaprevir less effective for HCV

For patients with chronic hepatitis C virus (HCV) infection, eight weeks of combined sofosbuvir-velpatasvir-voxilaprevir may not be as effective as 12 weeks of only sofosbuvir-velpatasvir, results from two phase 3…

Hepatitis C Civil Society Declaration launched

At the Hepatitis C Community Summit held on 18-19 April 2017 in Amsterdam, civil society and community organisations from all over Europe launched a declaration to address the urgent need…

Xpert point-of-care test represents major advance in hepatitis C diagnosis

Sydney, Australia – 22 April 2017: A new test that enables diagnosis of hepatitis C infection in a single visit could improve access to early diagnosis, monitoring, and treatment service…

Triplet treatment offers impressive results in resistant HCV

Combo pill highly effective despite presence of drug-resistant mutations AMSTERDAM -- A three-drug combination pill taken for 16 or 24 weeks led to sustained viral clearance in almost all patients…

EASL releases updated hepatitis B guidelines at International Liver Congress

The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection -- the first update since 2012…

Switching to TAF for hepatitis B improves kidney function and bone loss

People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss,…

Nivolumab increases survival for people with advanced liver cancer

The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well-tolerated as a treatment for advanced liver cancer that did not respond to standard therapy, researchers…

Solving the hepatitis C epidemic among people with substance abuse disorders

Annals of Internal Medicine editorial by UB professor describes innovations in HCV treatment at methadone clinics and corrections facilities BUFFALO, N.Y., April 24, 2017 — One of the most dramatic medical…

Blood donor screening for hepatitis E reveals incidence is higher than previously reported

Results from a hepatitis E virus (HEV) RNA screening centre in Germany suggest need for routine screening to prevent viral transmission to the immunocompromised April 21, 2017, Amsterdam, The Netherlands:…